Semaglutide FLOW Kidney and Heart Findings: What Patients Should Know
A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across...
Semaglutide and Bone Fracture Risk: What People With Type 2 Diabetes Should Know
An ENDO 2026 real-world study linked semaglutide with fewer bone fractures than several other weight-loss...
Review finds GLP-1 medicines may help some children with obesity or type 2 diabetes, but long-term safety data are still limited
A pediatric review found GLP-1 medicines may help selected children and teens with obesity or...
Retatrutide: Trial Evidence, Approval Status and Safety
Understand what retatrutide trials show, what remains uncertain, and why investigational status matters when reading...
Retatrutide Phase 3 Results: What People With Type 2 Diabetes Should Know
Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss...
Real-Time CGM During Hemodialysis: What a Randomized Trial Found
A randomized trial tested real-time CGM in insulin-treated adults receiving haemodialysis. Here is what improved...
Orforglipron vs Dapagliflozin in Type 2 Diabetes: What the ACHIEVE-2 Trial Found
ACHIEVE-2 compared oral orforglipron with dapagliflozin in adults with type 2 diabetes. Learn about HbA1c...
Omnipod Pod Correction: Under-Delivery Risk and What Users Should Check
Omnipod pod correction guide covering affected products, insulin under-delivery, high glucose, DKA risk, lot checks...
New Research Confirms GLP-1 Medications Protect the Heart, Not Just Blood Sugar
New Research Confirms GLP-1 Medications Protect the Heart, Not Just Blood Sugar: cardiovascular outcome trial...